Somatic BRCA2 loss-of-function in advanced EOC: PARPi (olaparib, niraparib, rucaparib) ap...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-BRCA2-SOMATIC-OVARIAN |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-OVARIAN |
| Sources | SRC-CIVIC SRC-ESMO-OVARIAN-2024 SRC-NCCN-OVARIAN-2025 |
Actionability Facts
| Biomarker | BIO-HRR-PANEL |
|---|---|
| Variant | BRCA2 somatic loss-of-function |
| Disease | DIS-OVARIAN |
| ESCAT tier | IA |
| Recommended combinations | olaparib monotherapy maintenance, rucaparib monotherapy maintenance, olaparib + bevacizumab (PAOLA-1) |
| Evidence summary | Somatic BRCA2 loss-of-function in advanced EOC: PARPi (olaparib, niraparib, rucaparib) approved regardless of germline status; SOLO1 EU label and rucaparib FDA label include sBRCA. ESCAT IA / OncoKB Level 1. |
Notes
Reflex germline testing recommended; ~30% of tumor-detected BRCA in EOC are germline.
Used By
No reverse references found in the YAML corpus.